crossmab antibody Search Results


crossmab antibody  (Paratopes)
90
Paratopes crossmab antibody
Crossmab Antibody, supplied by Paratopes, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crossmab antibody/product/Paratopes
Average 90 stars, based on 1 article reviews
crossmab antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
crossmab antibody  (Brinkmann Instruments)
90
Brinkmann Instruments crossmab antibody
Crossmab Antibody, supplied by Brinkmann Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/crossmab antibody/product/Brinkmann Instruments
Average 90 stars, based on 1 article reviews
crossmab antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
2 + 2 crossmab fab /fit-ig  (EpimAb Biotherapeutics)
90
EpimAb Biotherapeutics 2 + 2 crossmab fab /fit-ig
Major CrossMab formats: A) 1 + 1 CrossMab: CH −CL vanucizumab, faricimab, 10E8.4/iMab 1 + 1; B) 1 + 1 CrossMab VH-VL± : PD1-TIM3, PD1-LAG3; C) CrossMab CH −CL+/– based FAP-4-1BBL, CD19-4-1BBL fusion proteins; D) 2 + 1 CrossMab: CH −CL cibisatamab; E) 2 + 1 CrossMab VH-VL± : glofitamab, CC-93269, TYRP1-TCB, WT1-TCB, RG6123; F) 2 + <t>2</t> <t>CrossMab</t> CH −CL -based FIT-Ig EMB-01, EMB-02, EMB-06; G) 2 + 2 CrossMab: CH −CL FAP-DR5; H) 2 + 1 CrossMab VH-VL± : BS-GANT, FAP-CD40; I) 1 + 1 CrossMab CH −CL -based Nkp46-based NK cell engager (NKCE). Heavy-chain domains are depicted in dark colors and respective light-chain domains are depicted with corresponding bright colors. Fusion protein depicted in purple. Note: Differences in variable regions and/or isotype and Fc engineering are not depicted. Created with BioRender.com
2 + 2 Crossmab Fab /Fit Ig, supplied by EpimAb Biotherapeutics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/2 + 2 crossmab fab /fit-ig/product/EpimAb Biotherapeutics
Average 90 stars, based on 1 article reviews
2 + 2 crossmab fab /fit-ig - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


Major CrossMab formats: A) 1 + 1 CrossMab: CH −CL vanucizumab, faricimab, 10E8.4/iMab 1 + 1; B) 1 + 1 CrossMab VH-VL± : PD1-TIM3, PD1-LAG3; C) CrossMab CH −CL+/– based FAP-4-1BBL, CD19-4-1BBL fusion proteins; D) 2 + 1 CrossMab: CH −CL cibisatamab; E) 2 + 1 CrossMab VH-VL± : glofitamab, CC-93269, TYRP1-TCB, WT1-TCB, RG6123; F) 2 + 2 CrossMab CH −CL -based FIT-Ig EMB-01, EMB-02, EMB-06; G) 2 + 2 CrossMab: CH −CL FAP-DR5; H) 2 + 1 CrossMab VH-VL± : BS-GANT, FAP-CD40; I) 1 + 1 CrossMab CH −CL -based Nkp46-based NK cell engager (NKCE). Heavy-chain domains are depicted in dark colors and respective light-chain domains are depicted with corresponding bright colors. Fusion protein depicted in purple. Note: Differences in variable regions and/or isotype and Fc engineering are not depicted. Created with BioRender.com

Journal: mAbs

Article Title: Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

doi: 10.1080/19420862.2021.1967714

Figure Lengend Snippet: Major CrossMab formats: A) 1 + 1 CrossMab: CH −CL vanucizumab, faricimab, 10E8.4/iMab 1 + 1; B) 1 + 1 CrossMab VH-VL± : PD1-TIM3, PD1-LAG3; C) CrossMab CH −CL+/– based FAP-4-1BBL, CD19-4-1BBL fusion proteins; D) 2 + 1 CrossMab: CH −CL cibisatamab; E) 2 + 1 CrossMab VH-VL± : glofitamab, CC-93269, TYRP1-TCB, WT1-TCB, RG6123; F) 2 + 2 CrossMab CH −CL -based FIT-Ig EMB-01, EMB-02, EMB-06; G) 2 + 2 CrossMab: CH −CL FAP-DR5; H) 2 + 1 CrossMab VH-VL± : BS-GANT, FAP-CD40; I) 1 + 1 CrossMab CH −CL -based Nkp46-based NK cell engager (NKCE). Heavy-chain domains are depicted in dark colors and respective light-chain domains are depicted with corresponding bright colors. Fusion protein depicted in purple. Note: Differences in variable regions and/or isotype and Fc engineering are not depicted. Created with BioRender.com

Article Snippet: 11 , EMB-01 , EGFR/c-Met , 2 + 2 CrossMab Fab /FIT-Ig , Oncology , Ph 1 , EpimAb , 2019 , NCT03797391 , , .

Techniques:

CrossMabs in clinical trials (status July 2021), FP: Fusion protein, FIT-Ig: Fabs-in-tandem Ig, EIH: Entry into human date

Journal: mAbs

Article Title: Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins

doi: 10.1080/19420862.2021.1967714

Figure Lengend Snippet: CrossMabs in clinical trials (status July 2021), FP: Fusion protein, FIT-Ig: Fabs-in-tandem Ig, EIH: Entry into human date

Article Snippet: 11 , EMB-01 , EGFR/c-Met , 2 + 2 CrossMab Fab /FIT-Ig , Oncology , Ph 1 , EpimAb , 2019 , NCT03797391 , , .

Techniques: